Compare ACRS & AVNW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACRS | AVNW |
|---|---|---|
| Founded | 2012 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Radio And Television Broadcasting And Communications Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 311.0M | 275.0M |
| IPO Year | 2015 | 2007 |
| Metric | ACRS | AVNW |
|---|---|---|
| Price | $4.52 | $22.36 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | $10.20 | ★ $34.50 |
| AVG Volume (30 Days) | ★ 1.4M | 176.9K |
| Earning Date | 05-07-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 69.01 | N/A |
| EPS | N/A | ★ 0.45 |
| Revenue | $1,683,000.00 | ★ $243,858,000.00 |
| Revenue This Year | N/A | $5.59 |
| Revenue Next Year | $4.24 | $7.03 |
| P/E Ratio | ★ N/A | $51.21 |
| Revenue Growth | N/A | ★ 0.56 |
| 52 Week Low | $1.20 | $18.49 |
| 52 Week High | $4.89 | $27.02 |
| Indicator | ACRS | AVNW |
|---|---|---|
| Relative Strength Index (RSI) | 61.08 | 47.80 |
| Support Level | $3.16 | $20.86 |
| Resistance Level | $4.56 | $22.61 |
| Average True Range (ATR) | 0.23 | 0.99 |
| MACD | 0.00 | 0.11 |
| Stochastic Oscillator | 81.71 | 55.16 |
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.
Aviat Networks Inc provides wireless transport and access networking solutions designed to support telecommunications operators and private network providers situated in various countries. The company offers a range of microwave and millimeter wave radios, network management tools, and services that enable high-capacity, secure, and reliable data transport over wireless networks. Its products serve diverse clients including mobile operators, public safety organizations, utilities, government agencies, and enterprise customers. Aviat generates revenue from the sale of its networking equipment, professional services, and ongoing support contracts. Its operations cover various regions including the Americas, Europe, Asia Pacific, the Middle East, and Africa.